- Home
- BMRC vs ABEO Comparison
BMRC vs ABEO Comparison
Compare BMRC & ABEO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | BMRC | ABEO |
|---|---|---|
| Founded | 1989 | 1974 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 465.8M | 399.5M |
| IPO Year | 2007 | 2005 |
Fundamental Metrics
Financial Performance| Metric | BMRC | ABEO |
|---|---|---|
| Price | $28.47 | $7.29 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 3 | 3 |
| Target Price | ★ $28.67 | $20.00 |
| AVG Volume (30 Days) | 147.6K | ★ 1.1M |
| Earning Date | 04-27-2026 | 05-13-2026 |
| Dividend Yield | ★ 3.92% | N/A |
| EPS Growth | N/A | ★ 165.16 |
| EPS | ★ 1.11 | N/A |
| Revenue | N/A | ★ $2,998,000.00 |
| Revenue This Year | $391.81 | $1,024.31 |
| Revenue Next Year | $6.13 | $145.42 |
| P/E Ratio | $25.56 | ★ N/A |
| Revenue Growth | N/A | ★ 258.18 |
| 52 Week Low | $22.50 | $4.00 |
| 52 Week High | $30.92 | $7.54 |
Technical Indicators
Market Signals| Indicator | BMRC | ABEO |
|---|---|---|
| Relative Strength Index (RSI) | 48.59 | 67.45 |
| Support Level | $25.14 | $4.85 |
| Resistance Level | $29.93 | $7.36 |
| Average True Range (ATR) | 0.77 | 0.29 |
| MACD | -0.16 | 0.05 |
| Stochastic Oscillator | 15.88 | 95.92 |
Price Performance
Historical ComparisonAbout BMRC Bank of Marin Bancorp
Bank of Marin Bancorp is a United States-based bank holding company. It conducts business through its wholly-owned subsidiary. The Bank provides a wide range of financial services to customers such as professionals, small and middle-market businesses, and individuals residing in Marin, Sonoma, Napa, San Francisco, Alameda, Contra Costa, San Mateo counties, and others. The majority of its revenue comes from interest income.
About ABEO Abeona Therapeutics Inc.
Abeona Therapeutics Inc is a commercial-stage biopharmaceutical company. The company is focused on developing cell and gene therapies for life-threatening diseases. The company's ZEVASKYN (prademagene zamikeracel) is an autologous cell-based gene therapy for the treatment of wounds in adults and pediatric patients with recessive dystrophic epidermolysis bullosa (RDEB). The company's development portfolio includes adeno-associated virus (AAV)-based gene therapies for ophthalmic diseases with high unmet medical need.